Advertisement

Topics

Insmed’s Amikacin Moves Closer To US Market In Refractory Lung Disease

17:53 EDT 10 Aug 2018 | SCRIP

FDA panel's recommendation that liposome inhalation suspension be labeled only for refractory nontuberculous mycobacterial lung disease and not first-line use...

      

Related Stories

 

Original Article: Insmed’s Amikacin Moves Closer To US Market In Refractory Lung Disease

NEXT ARTICLE

More From BioPortfolio on "Insmed’s Amikacin Moves Closer To US Market In Refractory Lung Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...